Drug Profile
Tilavonemab - AbbVie/C2N Diagnostics
Alternative Names: ABBV-8E12; C2N-8E12Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator C2N Diagnostics
- Developer AbbVie; C2N Diagnostics
- Class Antibodies; Antiparkinsonians; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
- Discontinued Progressive supranuclear palsy
Most Recent Events
- 25 Aug 2022 AbbVie terminates a phase II trial in Alzheimer's disease (Early-stage disease) in Australia, Belgium, Canada, Denmark, Finland, Italy, New Zealand, Netherland, Sweden, Spain and USA due to lack of efficacy in parent study (IV) (NCT02880956)
- 30 Sep 2021 AbbVie completes phase II clinical trials in Alzheimer's disease (Early-stage disease) the US, Australia, Belgium, Canada, New Zealand and Sweden (IV) in September 2021 (NCT03712787) (EudraCT2018-000268-26)
- 05 Jul 2021 AbbVie completes phase II clinical trials in Alzheimer's disease (Early-stage disease) in the US, Australia, Belgium, Canada, Denmark, Finland, Italy, New Zealand, Netherland, Sweden and Spain (IV) (NCT02880956)